| Characteristic | 
        Median    (inter-quartile range) or %  | 
       
      
        | Date    of HAART initiation | 
        February    1998 (March 1997, February 2000) | 
       
      
        | Cumulative    NRTI use-years | 
        3.3 (1.6, 5.1) | 
       
      
        | Cumulative zidovudine use-years | 
        1.0 (0.5, 1.9) | 
       
      
        | Cumulative stavudine use-years | 
        0.5 (0.0, 1.0) | 
         
      
        | Cumulative abacavir use-years | 
        0.0 (0.0, 0.0) | 
       
      
        | Cumulative tenofovir use-years | 
        
          - (0.0,    0.0)
 
          | 
       
      
        | Cumulative    PI use-years | 
        0.5 (0.2, 0.6) | 
       
      
        | Cumulative    NNRTI use-years | 
        0.0 (0.0, 0.4) | 
       
      
        | Enrollment    Period 1994-1995 | 
        91% | 
       
      
        | Age,    yearsa | 
        38.7 (33.6, 44.1) | 
       
      
        Race/Ethnicity 
          African-American 
          Hispanic 
          White 
          Other | 
         56%  
            25%  
            16%  
          2%  | 
       
      
        | Alcohol    Use>3 drinks/weeka | 
        18% | 
       
      
        Cigarette Smokinga 
          Current 
          Former 
          Never | 
         51% 
            22% 
          27% | 
       
      
        | Marijuana    usesince last visit | 
        18% | 
       
      
        | Injection    drug, heroin, cocaine, or crack usesince last visit | 
        13% | 
       
      
        | Quality    of Lifea | 
        65.5 (48.4, 79.5) | 
       
      
        | CESD> 16a | 
        49% | 
       
      
        Highest    education level attained 
          Graduated college or higher 
          Some College 
          Completed High School 
          Did not complete high school | 
         8% 
            25% 
            31% 
          37% | 
       
      
        | Have    AIDSa | 
        40% | 
       
      
        CD4    cell count, cells/mm3a 
          <100 
          100-<200 
          200-<500 
          ≥ 500 | 
         15% 
            18% 
            51% 
          15% | 
       
      
        | log10HIVRNA,    copies/mla | 
        4.2 (3.3, 4.8)  | 
       
      |